The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

Bays, Harold; Roth, Eli M.; McKenney, James M.; Kelly, Maureen; Thakker, Kamlesh M.; Setze, Carolyn M.; Obermeyer, K.; Sleep, Darryl J.

doi:10.2337/dc10-0357

Cited by 16 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results indicate a similar AE profile between the different FA + statin combination treatments. Furthermore, when the safety profile was examined according to the presence or not of metabolic syndrome, or in patients with T2DM, the AEs were similar with those observed in the overall population [27, 31]. Additionally, the long-term safety of FA + statin was tested for up to 2 years [25, 26].…”

Section: Safety and Tolerability Of Fa + Statin Combinationmentioning

confidence: 99%

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

Filippatos

2012

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

show abstract

Section: Safety and Tolerability Of Fa + Statin Combinationmentioning

confidence: 99%

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

Filippatos

2012

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…Clinical trials of fenofibric acid 135 mg/day in combination with simvastatin, atorvastatin or rosuvastatin at various doses have shown additional benefits on lipid levels compared with statins alone. 56,57 …”

Section: Fenofibratementioning

confidence: 99%

Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes

Standl

2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Diabetes is a significant risk factor for the development of cardiovascular disease (CVD), particularly in the presence of high blood pressure, poor glycaemic control and high total cholesterol. While efforts to control blood pressure or blood glucose beyond levels considered ‘normal’ in patients with diabetes have not produced the expected reduction in CVD, treatment with statins to reduce levels of low-density lipoprotein cholesterol (LDL-C) has been much more successful. However, many patients with diabetes who receive statins (even at high doses) remain at significant residual risk of CVD due to the presence of atherogenic dyslipidaemia. Markers of persisting risk include low levels of high-density lipoprotein cholesterol (HDL-C), high levels of triglycerides (TG) and LDL-C levels above target despite high-dose statin therapy. Combining statins with drugs that target HDL-C and TG, such as fibrates, niacin and omega-3 polyunsaturated fatty acid (PUFA) ethyl esters, may offer further protection from CVD in patients with diabetes.

show abstract

“…The Severe Asthma Research Program has also described a cluster of older obese women with late onset non-atopic asthma [25]. Obesity being linked to systemic inflammation [26, 27], dyslipidemia, and metabolic syndrome [28] (where statins may be indicated) [29, 30], presents a unique opportunity for those with the obese-asthma phenotype. This subpopulation of asthmatics could potentially benefit from statins – a safe and widely used treatment that would also treat other comorbidities (e.g.…”

Section: Proposed Target Asthma Populationmentioning

confidence: 99%

Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research

Zeki¹,

Kenyon²,

Goldkorn³

2011

DML

View full text Add to dashboard Cite

The chance discovery of hydroxymethylglutaryl (HMG)-CoA reductase inhibitors has revolutionized the care of patients with cardiovascular disease. The unexpected finding that these cholesterol-lowering drugs (or ‘statins’) also posses pleiotropic immunomodulatory properties, has opened a new area of research which investigates the anti-inflammatory and anti-proliferative properties of statins. In this brief commentary, we discuss the potential application of these drugs in asthma, where metabolic pathways pertinent to lung inflammation, in addition to the mevalonate cascade, may be targeted. We review mechanisms of action, discuss the potential therapeutic use of statins in asthma, share some preliminary data from our laboratory, discuss results from recent clinical trials in asthma, and propose a new target asthma subpopulation that could potentially benefit. We conclude our essay by highlighting the mevalonate-dependent and –independent pathways that may be modulated by statins, including the emerging area of cholesterol, sphingolipid, and lipid raft biology in lung disease. In this is an opportunity to develop new treatments for asthma, where innovative therapies are urgently needed to prevent acute exacerbations and alter disease progression.

show abstract

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

Cited by 16 publications

References 8 publications

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes

Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research

Contact Info

Product

Resources

About